ROSSOSEQ
LIVE

Serial Number

79115209

Owner

Pro Bono Bio Entrepreneur Limited

Attorney

Roberta S. Bren

Filing Date

Mar 5, 2012

Add to watchlist:

No watchlists yet
View on USPTO

ROSSOSEQ Trademark

Serial Number: 79115209 • Registration: 4441775

ROSSOSEQ is a trademark filed by Pro Bono Bio Entrepreneur Limited on March 5, 2012. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Pro Bono Bio Entrepreneur Limited (10 trademarks)

4th floor,

Entity Type: 99

Trademark Details

Filing Date

March 5, 2012

Registration Date

December 3, 2013

Published for Opposition

September 17, 2013

Cancellation Date

March 5, 2022

Goods & Services

Pharmaceutical preparations and substances for the treatment of inflammatory skin conditions; veterinary and sanitary preparations and substances for the treatment of inflammatory skin conditions; chemical preparations for pharmaceutical purposes, namely, for the treatment of inflammation of the skin, pain and psoriasis; topical preparations, namely, liquids, gels, creams, lotions and sprays for the treatment of inflammation and pain; pharmaceutical preparations in the form of vesicles for the treatment of pain and inflammatory skin conditions; parenteral preparations, namely, sterile preparations in the form of vesicles for injection, infusion or implantation into the human body for the treatment of inflammatory skin conditions; chemical preparations in the form of vesicles, namely, liquids, gels, creams, lotions and sprays for the treatment of pain and inflammatory skin conditions for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammatory skin conditions; dispersions and dry preparations of liposomal active substance carriers for use as a pharmaceutical, cosmetic substance carrier, in the nature of a liquid, gel, cream, lotion or lipid; pharmaceutical cosmetic and veterinary substances for the treatment of pain and inflammatory skin conditions; pharmaceuticals for medical use for the treatment of pain and inflammatory skin conditions; topical and parenteral pharmaceutical lipids for the treatment of pain and inflammatory skin conditions; cosmeceutical preparations in the nature of medicated cosmetics; local anesthetics; topical cream for treating inflammatory skin conditions; medicated topical dispersions, medicated topical lotions, medicated topical ointments, medicated topical gels, medicated topical sprays, medicated topical lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain and inflammatory skin conditions; surfactants for medical use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, treatment of inflammation, atopic eczema, dishydrotic hand eczema, plaque-type psoriasis, seborrhoeic eczema, acne vulgaris, pain or fungal infection, and disorders related to the skin

Medical devices in the nature of a carrier with nanostructures which cross through the skin for the treatment of dermal conditions associated with deep layers of the skin beneath the epidermis; molecular filtering devices for medical use, namely, a gel, liquid or cream preparation as a drug delivery device which filters through the skin and has a physical therapeutic effect at the point of complaint; medical, veterinary and surgical devices, namely, a medical device which acts as a drug delivery device in the nature of non-pharmaceutical nanostructures that migrate through the skin, which is used to reduce irritation, swelling or inflammation and target the symptoms of inflammatory skin conditions; inhalers for medical purposes sold empty; injection devices, namely, medical fluid injectors and medical syringes; medical instruments and devices for the administration of skin disease therapy and prophylaxis preparations and substances

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Oct 1, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Oct 1, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jan 22, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Dec 23, 2021 INTS
INVALIDATION PROCESSED
Dec 22, 2021 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 26, 2021 INTR
CANCELLED SECTION 71
Feb 26, 2021 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Jan 3, 2020 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 3, 2018 REM3
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 14, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 14, 2016 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 21, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 4, 2014 FICS
FINAL DISPOSITION PROCESSED
Mar 4, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 3, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 3, 2013 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 17, 2013 NPUB
PUBLISHED FOR OPPOSITION
Sep 17, 2013 PUBO
NOTIFICATION PROCESSED BY IB
Sep 15, 2013 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 28, 2013 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 28, 2013 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 28, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 14, 2013 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 7, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 23, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 23, 2013 CRFA
ASSIGNED TO LIE
Jul 22, 2013 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 15, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 6, 2013 GNRN
NON-FINAL ACTION E-MAILED
Mar 6, 2013 GNRT
NON-FINAL ACTION WRITTEN
Mar 6, 2013 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 12, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 12, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 12, 2013 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 11, 2013 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 11, 2013 REAP
REFUSAL PROCESSED BY IB
Sep 1, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 14, 2012 RFCS
REFUSAL PROCESSED BY MPU
Aug 14, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 14, 2012 RFCR
APPLICATION FILING RECEIPT MAILED
Aug 14, 2012 MAFR
NON-FINAL ACTION WRITTEN
Aug 13, 2012 CNRT
ASSIGNED TO EXAMINER
Aug 8, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 8, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 2, 2012 REPR